文献速递银屑病与炎症性皮肤病

按银屑病严重程度分层的银屑病关节炎发病率与患病率:美国电子健康记录数据库回顾性分析

Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States.
PubMed 文献 · J Am Acad Dermatol · 2021-09-20

该研究基于美国Optum电子健康记录数据库,以治疗类型作为银屑病严重程度的替代指标,评估银屑病患者中银屑病关节炎的发病率与患病率。总体银屑病关节炎发病率为每100患者年2.9例(95%CI 2.9-3.0),轻度、中度、重度银屑病分别为2.1、9.9、17.6例每100患者年。排除银屑病诊断后1年内确诊银屑病关节炎的患者后,总体发病率降至1.7例每100患者年。

要点

  • 银屑病患者银屑病关节炎总体发病率为每100患者年2.9例。
  • 按治疗类型分层,轻度、中度、重度银屑病关节炎发病率分别为2.1、9.9、17.6例每100患者年。
  • 银屑病关节炎风险随银屑病严重程度增加而升高,重度患者最高。

核心结论

  • 银屑病患者发生银屑病关节炎的风险随疾病严重程度增加而升高,重度银屑病患者风险最高。

研究设计与样本

  • 基于美国Optum电子健康记录数据库的回顾性分析。
  • 以治疗类型(非系统性治疗、非生物制剂系统性治疗、生物制剂)作为银屑病严重程度的替代指标进行分层。
  • 评估银屑病患者中银屑病关节炎的发病率(每100患者年)和患病率。
  • 发病率从银屑病诊断时及诊断后1年两个时间点评估。

主要发现

  • 银屑病关节炎总体发病率为每100患者年2.9例(95%CI 2.9-3.0)。
  • 轻度、中度、重度银屑病的银屑病关节炎发病率分别为每100患者年2.1例(95%CI 2.1-2.1)、9.9例(95%CI 9.5-10.4)、17.6例(95%CI 16.9-18.3)。
  • 排除银屑病诊断后1年内确诊银屑病关节炎的患者后,总体发病率降至每100患者年1.7例(95%CI 1.6-1.7),各治疗严重程度替代指标组趋势相似。

临床怎么用

  • 临床中应关注银屑病患者的银屑病关节炎风险,尤其是重度银屑病患者。
  • 治疗类型可作为银屑病严重程度的替代指标,辅助评估银屑病关节炎风险。

局限性

  • 结果可能无法推广至更广泛的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Among patients in the United States with psoriasis (PsO), limited data exist on the incidence and prevalence of psoriatic arthritis (PsA) based on disease severity. OBJECTIVE: To assess the incidence, prevalence, and predictors of PsA among patients with PsO stratified by PsO severity using treatment type. METHODS: Incidence of PsA per 100 PsO patient-years (PY) and prevalence were assessed using the Optum electronic health records database. Incidence was assessed from PsO diagnosis and 1 year after PsO diagnosis overall and stratified by mutually exclusive treatment classes as a severity surrogate. RESULTS: The overall incidence of PsA was 2.9 (95% CI, 2.9-3.0) events per 100 PY. The incidence (95% CI) by severity surrogate was 2.1 (2.1-2.1), 9.9 (9.5-10.4), and 17.6 (16.9-18.3) events per 100 PY for patients with mild, moderate, and severe PsO as determined by receiving nonsystemics, nonbiologic systemic therapy, and biologics, respectively. When excluding patients diagnosed with PsA 1 year after PsO diagnosis, overall incidence was lower (1.7 [95% CI, 1.6-1.7] events per 100 PY), with similar trends for treatment-severity surrogates. LIMITATIONS: Results may not be generalizable to a wider population. CONCLUSION: The risk of developing PsA increased with disease severity and was highest in patients with the most severe PsO.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Merola JF, Tian H, Patil D, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2021. PMID: 34547358. doi:10.1016/j.jaad.2021.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。